Staphylococcus epidermidis: A significant nosocomial pathogen

Protection against endocarditis due to Staphylococcus epidermidis by immunization with capsular polysaccharide/adhesin.

“…Although we have not tested the role of staphylococcal PS/A in mediating adherence to all of the specific materials used in prosthetic valve surgery, considerable clinical experience suggests that S. epidermidis avidly colonizes and infects a wide range of prosthetic materials of various compositions. 10,13,15,[30][31][32] On the other hand, it is possible that antibody to S. epidermidis polysaccharide protects against infection by a more conventional immune mechanism, opsonophagocytosis of bacteria in blood. In addition to functioning as an adhesin, PS/A is an important component of the capsule of S. epidermidis.…”

“…Monoclonal antibody was prepared by standard techniques25 after hyperimmunization of BALB/c mice with 10 (Figure 1). The pump was filled with 2 ml of 10,000 units/ml heparin, which was delivered continuously for 7 days at 10 ,1/hr.…”

Necrotizing otitis externa caused by Staphylococcus epidermidis

“…epidermidis is usually a nonpathogenic commensal organism [11]; however, its role in infection is now well established following total hip replacement by prosthesis and wounds after cardiac surgery, as well as after bone marrow transplantation [5,11]. Because of its frequent resistance to all penicillins and cephalosporins, treatment can be very difficult [11], and there is a high risk of complications (such as pseudomembranous colitis following long-term antibiotic treatment). Combining clindamycin, teicoplanin or vancomycin with rifampin seems to be effective against Staph.…”

Study of Antimicrobial activity of selected Iranian plant extracts on vancomycin resistant Staphylococcus epidermidis

“…Staphylococcus epidermidis is a significant pathogenic bacterium which causes a wide range of infections that sometimes can lead to the death of the infected person [1,2]. The increase in nosocomial infection rate at healthcare and medical institutions largely contributes to the growing economic burden for treating infections.…”